Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer
Launched by NAVY GENERAL HOSPITAL, BEIJING · May 15, 2016
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
To evaluate the efficacy of letrozole and clomiphene in PCOS patients is important,especially in resistent PCOS patients. Although most medications prove the effectiveness of letrozole and clomiphene,the subjects of letrozole and sequential clomiphene in PCOS patients are rarely.The trial may provide further basis for this medication in PCOS patients in ovulation. If the medication demonstrates efficacy, the method would help the patients with PCOS to deal with the problem of infertility.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women with PCOS
- Exclusion Criteria:
- • •Women more than 38 years or less than 20 years
- • With infectious diseases or endocrine diseases
- • Who refuse to participate in the experiment
About Navy General Hospital, Beijing
Navy General Hospital in Beijing is a prominent medical institution dedicated to advancing healthcare through innovative clinical research and trials. As a leading sponsor of clinical studies, the hospital focuses on a wide range of therapeutic areas, aiming to enhance patient outcomes and contribute to medical knowledge. With a robust infrastructure, a team of experienced researchers, and a commitment to ethical standards, Navy General Hospital fosters collaborations with various stakeholders to ensure the successful execution of clinical trials that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Aiming Wang, Dr
Principal Investigator
Navy General Hospital, Beijing
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials